Shared on30 Jul 25Fair value Increased 102%
Vir Biotechnology's fair value outlook has notably improved, as bullish analyst sentiment driven by promising early Phase 1 data for VIR-5500 in mCRPC and long-term market potential outweigh concerns over competition and cash burn, resulting in a consensus price target increase from $8.71 to $17.62. Analyst Commentary Bullish analysts highlight compelling early Phase 1 data for VIR-5500 in heavily pretreated metastatic castration-resistant prostate cancer (mCRPC) patients.
Shared on01 May 25Fair value Increased 0.69%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on24 Apr 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on17 Apr 25Fair value Decreased 2.81%
AnalystConsensusTarget has decreased profit margin from 19.3% to 17.3%.
Shared on09 Apr 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on02 Apr 25Fair value Decreased 72%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on26 Mar 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.